{"filings":[{"id":68008,"accession_number":"0000929638-26-001834","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2026-05-13T20:05:35+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 rev $8.9M (+2%); net loss $5.1M; DrugSorb-ATR FDA submission delayed to late 2026/early 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.9M, +2% YoY; gross margin 69% vs 71% in Q1 2025.","Net loss $5.1M ($0.08/share) vs $1.5M ($0.02) in Q1 2025, driven by non-cash FX; adjusted net loss improved to $3.4M ($0.05).","Cash $6.4M vs $7.8M Dec 31; cash burn $1.1M (excl. $0.3M restructuring); targeting operating cash flow breakeven H2 2026.","DrugSorb-ATR for Brilinta: new De Novo submission delayed to late 2026/early 2027 after FDA requested additional mechanistic data.","Distributor orders delayed ~$500k in Middle East due to U.S.-Iran war; Germany direct sales slightly down but with smaller team."],"consensus_eps_estimate":-0.0561,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":8864000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91681,"accession_number":"0001104659-26-038859","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CytoSorbents receives Nasdaq extension to Sept 28, 2026 for minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension until Sept 28, 2026 to regain $1.00 minimum bid price compliance.","Previously failed to meet compliance by March 31, 2026; had been notified in October 2025.","Company considering options including reverse stock split to regain compliance.","No assurance of regaining compliance; delisting risk remains.","No immediate effect on listing or SEC reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101918,"accession_number":"0000929638-26-001150","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CytoSorbents Q4/FY2025: Revenue $37.1M (+4% YoY), net loss improves to $8.2M; targets H2 2026 cash breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.","Adjusted net loss $14.2M ($0.23/sh) flat per share; adjusted EBITDA loss $10.5M improved from $11.5M.","Cash $7.8M at Dec 31, 2025; amended credit facility added $2.5M; workforce reduced 10% in Q4.","Targets cash flow breakeven in H2 2026; ongoing FDA discussions for DrugSorb-ATR De Novo submission (timing TBD).","Direct sales outside Germany +13%, distributor sales +11.4%; Germany sales -10% due to restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118254,"accession_number":"0000929638-25-004243","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents Reports Q3 2025 Revenue of $9.5M, Up 10% YoY, and Provides Business Update","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue was $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024, driven by record distributor sales.","Amended credit agreement with Avenue Capital Group added $2.5 million in term loans and extended interest-only period to December 31, 2026.","Workforce reduction of approximately 10% implemented to accelerate path to cash-flow breakeven by Q1 2026, with up to $900,000 in restructuring charges.","Pre-submission meeting request for DrugSorb-ATR De Novo application submitted to FDA; formal submission expected Q1 2026 with regulatory decision anticipated mid-2026.","Gross margin improved to 70% from 61% a year ago; operating loss narrowed to $2.9 million from $4.8 million."],"consensus_eps_estimate":-0.0476,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":27829000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118253,"accession_number":"0001104659-25-096675","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CytoSorbents (CTSO) receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 2, 2025, for non-compliance with Minimum Bid Price Requirement.","Stock traded below $1.00 per share for 30 consecutive business days prior to notice.","Company has 180 calendar days, until March 31, 2026, to regain compliance.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days.","If not cured by deadline, may qualify for another 180-day period with a compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134698,"accession_number":"0000929638-25-003494","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CytoSorbents to file new DrugSorb-ATR De Novo application after FDA appeal upholds denial but offers expedited path","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA appeal upheld prior De Novo denial for DrugSorb-ATR, citing need for additional label-indication data; no safety issues found.","Company will file new De Novo application with new real-world data; expects expedited review under Breakthrough Device designation.","Pre-submission meeting request to FDA next month; formal meeting anticipated in Q4 2025; standard decision expected mid-2026.","Withdrew Health Canada Request for Reconsideration; will submit new application after FDA clarity.","Management focuses on core business growth, cost control, and near breakeven by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134697,"accession_number":"0001104659-25-080908","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA upholds DrugSorb-ATR De Novo denial but offers path forward","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA appeal decision found no safety issues with DrugSorb-ATR but upheld the prior De Novo denial.","FDA proposed a potential path to market authorization; Company discussing details with the Agency.","Another appeal avenue with CDRH Director is available within 30 days; Company evaluating.","CEO states resolution of majority of outstanding issues; device remains an FDA Breakthrough Device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134696,"accession_number":"0000929638-25-002927","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.","Net income $1.9M ($0.03/share) vs net loss $4.3M in Q2 2024; adjusted net loss $3.7M vs $2.8M.","Adjusted EBITDA loss $2.6M vs $2.2M in Q2 2024; cash $11.7M at quarter end.","FDA appeal for DrugSorb-ATR held in July; administrative review expected by end of August 2025.","Health Canada reconsideration filed; will proceed after FDA decision."],"consensus_eps_estimate":-0.051,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":18344000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134695,"accession_number":"0001104659-25-072805","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents highlights new sepsis studies showing improved survival with early, intensive CytoSorb use","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Meta-analysis of 744 septic shock patients: CytoSorb reduced in-hospital mortality (OR 0.64, p=0.036) and halved 28–30 day mortality (OR 0.46, p=0.003).","Berlot et al. study of 175 patients: early intensive CytoSorb use (≥3 cartridges in 2–3 days) nearly doubled survival (70% observed vs 37% predicted).","100-patient U.S. COVID-19 registry on ECMO: 74% 90-day survival, rising to 82% with early treatment, outperforming ~50% benchmarks.","Company to host World Sepsis Day Global Webinar on September 10, 2025 to discuss CytoSorb best practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134694,"accession_number":"0001104659-25-065280","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents: FDA appeal hearing set; Health Canada refuses DrugSorb-ATR license","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed appeal hearing under 21 CFR 10.75; supervisory review expected to complete by end of August 2025.","Health Canada issued Notice of Refusal for DrugSorb-ATR Medical Device License, citing non-compliance with regulations.","Company intends to file Level 1 Request for Reconsideration with Health Canada by July 25, 2025.","DrugSorb-ATR is an FDA Breakthrough Device to reduce bleeding in CABG surgery patients on Brilinta (ticagrelor).","CEO states no approved therapies exist in U.S. or Canada; final regulatory decisions expected by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151609,"accession_number":"0001104659-25-062097","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents appeals FDA denial of DrugSorb-ATR De Novo request; decision expected ~60 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Appeal filed June 18, 2025 under 21 CFR 10.75; FDA denial letter dated April 25, 2025.","DrugSorb-ATR designed to reduce bleeding risk in CABG patients on Brilinta; had Breakthrough Device Designation.","Supervisory review includes formal hearing with CDRH senior management; final decision typical within 60 days.","Health Canada review remains ongoing; company expects a regulatory decision in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151608,"accession_number":"0001104659-25-059466","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytoSorbents shareholders elect directors, approve executive compensation and auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees (Phillip P. Chan, Edward R. Jones, Michael Bator, Alan D. Sobel, Jiny Kim) were elected with strong support.","Non-binding advisory vote on named executive officer compensation passed with 18,189,951 for, 1,720,512 against, and 2,741,091 abstain.","Ratification of WithumSmith+Brown, PC as independent auditor for fiscal year 2025 approved with 39,485,868 for and 553,680 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151607,"accession_number":"0001104659-25-058561","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CytoSorbents Series B Right Warrants expire worthless; VWAP below $2.00 minimum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5-day VWAP prior to June 10, 2025, was below the $2.00 minimum required price.","Series B Right Warrants from the Rights Offering expired worthless per their terms.","Any payments received for exercise of Series B warrants will be refunded without interest or penalty.","Event triggers automatic termination of the warrant rights; stock closed below threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151606,"accession_number":"0001104659-25-048520","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents Q1 product rev $8.7M (-3%); FDA denies DrugSorb-ATR De Novo","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $8.7M, flat constant currency vs Q1 2024 $9.0M; gross margin 71% vs 77%.","Net loss improved to $1.5M ($0.02/shr) from $6.1M; adjusted net loss $3.7M ($0.06/shr).","FDA denied DrugSorb-ATR De Novo on Apr 25, 2025; company plans formal appeal for 2025 decision.","Rights offering raised $6.8M net; cash & restricted cash $13.1M at Mar 31 vs $9.8M Dec 31.","Germany sales disruption offset by E.U. distributor growth; opened Dubai subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":8727238.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151605,"accession_number":"0001104659-25-043534","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents receives FDA denial for DrugSorb-ATR De Novo; plans appeal if unresolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued denial letter on April 25, 2025 for DrugSorb-ATR De Novo Request, citing remaining deficiencies.","DrugSorb-ATR is a Breakthrough Device to reduce bleeding in CABG surgery patients on Brilinta.","CytoSorbents has met with FDA and will continue discussions; formal appeal due within 60 days if unresolved.","CEO expects final regulatory decision still in 2025 despite the denial.","No therapies currently approved in U.S. for this indication; tens of thousands of patients at risk annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151604,"accession_number":"0001104659-25-036004","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoSorbents appoints Melanie Grossman as VP & Corp Controller; issues inducement options and RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment of Melanie Grossman as VP and Corporate Controller, effective April 14, 2025.","Inducement grant includes 25,000 options at $0.99 exercise price, 10-year term, vesting 50% year 1 then 25% annually.","Also granted 35,000 signing RSUs (change-of-control or 4-year cliff) and 35,000 change-of-control RSUs.","Grossman brings 25 years of experience; previously SVP & Group Controller at Staffing 360 and auditor at Ernst & Young."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151603,"accession_number":"0001104659-25-034793","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoSorbents appoints Thomas Shannon as VP of Marketing for North America ahead of DrugSorb-ATR launch","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Shannon appointed VP of Marketing, North America; will lead strategy for DrugSorb-ATR in U.S. and Canada.","Shannon has 25+ years commercializing cardiovascular and critical care devices at Fresenius, Getinge, Medtronic.","DrugSorb-ATR is an FDA Breakthrough device for perioperative bleeding in CABG patients on Brilinta; regulatory decisions expected in 2025.","CEO Dr. Phillip Chan highlights Shannon's expertise as 'invaluable' for commercialization as company awaits FDA/Health Canada approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151602,"accession_number":"0001104659-25-031979","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents extends Series B Right Warrant expiration to June 10, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expiration date extended from April 10, 2025 to June 10, 2025.","Exercise price set at 90% of 5-day VWAP, with floor $2.00 and cap $4.00.","Approximately 4.8 million shares of common stock remain reserved for warrant exercise.","Holders must pay the maximum $4.00 per warrant; difference refunded based on final price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170458,"accession_number":"0001104659-25-029974","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents Q4 product rev $9.2M (+25% YoY); FY rev $35.6M (+15%); expects FDA decision 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $9.2M (+25% YoY); product gross margin 71%; operating loss improved 61% to $3.7M.","Adjusted net loss improved 78% to $1.7M ($0.03 per share) vs $7.8M loss in Q4 2023.","Full year product revenue $35.6M (+15%); net loss $20.7M ($0.38 per share); adjusted net loss $12.7M ($0.23 per share).","Cash $9.8M at Dec 31; pro forma $17M after $7.3M rights offering net proceeds.","Expects DrugSorb-ATR FDA & Health Canada decisions in 2025; Q1 2025 product sales to decline due to Germany restructure."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":8727238.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170457,"accession_number":"0001104659-25-029887","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"CytoSorbents restates 2023/2024 financials due to inventory and RSU errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overstated inventory from clerical error; understated non-cash RSU expense due to using vesting-date fair value instead of grant-date.","Non-reliance applies to audited FY2023 10-K and unaudited Q1-Q3 2023 and Q1-Q3 2024 quarterly reports.","Restated financials will be included in the 2024 Annual Report on Form 10-K; prior reports should not be relied upon until then.","Audit committee and management discussed the errors with the independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170456,"accession_number":"0001104659-25-026391","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CytoSorbents reschedules earnings call to March 31; reaffirms Q4 product revenue $9.0-$9.2M (22-25% growth)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.","Q4 product revenue expected $9.0-$9.2M (+22-25% YoY); full-year product revenue $35.4-$35.6M (+14% YoY).","Q4 product gross margin ~70%, vs 61% prior quarter and 72% prior year.","Pro-forma cash balance at Dec 31, 2024 ~$17.0M (unrestricted $15.5M); net Q4 cash burn ~$2.5M.","DrugSorb-ATR marketing applications under FDA and Health Canada review; regulatory decisions expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170455,"accession_number":"0001104659-25-020296","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CytoSorbents postpones Q4/FY2024 earnings to March 25 after controller's death; reaffirms prelim revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 product revenue expected $9.0-9.2M (22-25% YoY growth); full-year $35.4-35.6M (~14% growth).","Q4 product gross margin ~70%, vs 61% prior quarter and 72% Q4 2023.","Pro-forma cash balance Dec 31, 2024 ~$17.0M (incl. $7.3M net from rights offering/warrants); Q4 cash burn ~$2.5M.","DrugSorb-ATR marketing applications under substantive review with FDA and Health Canada; decisions expected in 2025.","Delay due to unexpected passing of VP and Corporate Controller James E. Cason, Jr.; earnings call rescheduled to March 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170454,"accession_number":"0001104659-25-016711","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoSorbents raises $1.6M from Series A warrant exercises; total rights offering proceeds $7.85M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,417,208 Series A Right Warrants exercised at $1.13 each for $1.6M gross proceeds upon expiration.","Total rights offering gross proceeds reached $7.85M; net liquidity increased by ~$12.3M after restricted cash released.","Approximately 4.8M shares remain reserved for Series B Right Warrants, exercisable until April 10, 2025.","CEO notes progress on DrugSorb-ATR regulatory applications with U.S. FDA and Health Canada, expecting decisions in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170453,"accession_number":"0001104659-25-002898","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CytoSorbents closes oversubscribed rights offering, raises $6.25M, unlocks $5M restricted cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights offering raised $6.25M gross from all 6.25M Units; oversubscribed 68% with 10.5M Units demanded.","Proceeds satisfy debt covenant, releasing $5.0M of restricted cash; net liquidity increase ~$10.8M.","Preliminary unaudited cash (incl. restricted) at Dec 31, 2024: $9.6M; pro forma $15.4M unrestricted $13.9M.","Q4 2024 cash burn est. $2.6M vs Q3 $2.7M; full audited results expected March 6, 2025.","Right Warrants exercisable at 90% of VWAP; Series A floor $1.00 cap $2.00, Series B floor $2.00 cap $4.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170452,"accession_number":"0001104659-25-001341","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents opens regional sales subsidiary in Dubai, UAE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New subsidiary in Dubai Science Park will serve as a sales hub for the Middle East and Africa.","Dr. Phillip Chan cites growing regional demand for critical care and cardiac surgery therapies.","Subsidiary aims to strengthen existing partnerships, support customers, and drive sales growth.","Dubai was chosen for its strategic location, strong economy, favorable tax policies, and advanced healthcare infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170451,"accession_number":"0001104659-25-000811","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents reports preliminary Q4 product revenue $9.0M-$9.2M, 22-25% YoY growth; full-year ~$35.5M, 14% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.","Full-year 2024 product revenue est $35.4M-$35.6M, ~14% growth vs $31.1M in FY 2023.","Q4 gross margin est ~70%, up from 61% in Q3 2024, driven by resolution of manufacturing issues.","Rights offering commenced Dec 23, 2024; subscription period ends Jan 10, 2025.","FDA and Health Canada reviews for DrugSorb-ATR marketing application underway; decisions expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":35594520.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187441,"accession_number":"0001104659-24-131274","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CytoSorbents commences rights offering at $1.00/unit, expiring Jan 10, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date Dec 16, 2024; one Subscription Right per share of common stock owned.","Each Subscription Right allows purchase of one Unit at $1.00, consisting of one share and two Right Warrants.","Expiration at 5:00 PM EST on January 10, 2025; oversubscription privilege available.","D.F. King & Co., Inc. is information agent; Moody Capital Solutions is dealer manager.","Stockholders holding in street name must instruct brokers by deadline; physical certificates for registered holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187440,"accession_number":"0001104659-24-126518","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CytoSorbents launches rights offering of up to 6.25M units at $1.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date Dec 16, 2024; basic rights expire Jan 10, 2025; subscription price $1.00 per unit.","Each unit: 1 share common stock, 1 Series A warrant (floor $1.00, cap $2.00), 1 Series B warrant (floor $2.00, cap $4.00).","Rights non-transferable; oversubscription privilege available if basic rights exercised in full.","Maximum 6,250,000 units offered; 12,500,000 shares overall including warrant exercises.","Unsubscribed rights expire worthless, diluting non-participating holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187439,"accession_number":"0001104659-24-115296","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents reports Q3 product revenue $8.6M (+11% YoY); net loss narrows to $2.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $8.6M (+11% YoY); total revenue $9.4M; net loss $2.3M ($0.04/sh) vs $9.2M loss in Q3 2023.","Product gross margins fell to 61% from 72% due to production slowdown and manufacturing issue now resolved.","Adjusted EBITDA loss improved to $3.6M from $5.6M in Q3 2023; cash $12.2M at quarter-end vs $14.9M Q2 2024.","DrugSorb-ATR De Novo application submitted to FDA Sep 27, accepted for review Oct 22; eligible for priority review.","Received MDSAP certification Nov 1; submitted MDL application to Health Canada Nov 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":29071316.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187438,"accession_number":"0001104659-24-105024","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytoSorbents authorizes up to $20M ATM equity offering of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company authorized offer and sale of up to $20M common stock under Open Market Sale Agreement with Jefferies LLC.","Registration statement on Form S-3 (No. 333-281062) declared effective by SEC on September 30, 2024.","Legal opinion of Morgan Lewis & Bockius LLP on legality of issuance filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187437,"accession_number":"0001104659-24-104669","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CytoSorbents submits DrugSorb-ATR FDA De Novo for CABG bleeding; Q3 sales $8.3-8.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DrugSorb-ATR De Novo application submitted to FDA on Sept 27, 2024 for reducing perioperative bleeding in CABG patients on ticagrelor.","FDA Breakthrough Device Designation, eligible for priority review; decision expected in 2025.","Health Canada MDL application complete, pending MDSAP certification for submission; decision also expected 2025.","Q3 2024 product sales estimated $8.3M-$8.5M, up 7-10% YoY from $7.8M.","Q3 product gross margin estimated 50-60% vs 71% due to production slowdown; issue resolved, normalized margins expected Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203961,"accession_number":"0001104659-24-091315","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"CytoSorbents amends royalty agreement with ROKK, redefines gross revenue scope","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty rate remains 3% of gross revenues from CytoSorb sales under amended agreement.","Amended and Restated Agreement clarifies definitions of 'gross revenue' with specified deductions.","Covered Products now explicitly include CytoSorb, VetResQ, ECOS-300CY, and certain DrugSorb versions.","Agreement dated August 16, 2024, amends the original 2003 Letter Agreement with ROKK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203960,"accession_number":"0001104659-24-090567","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CytoSorbents appoints Peter J. Mariani as CFO; Kathleen P. Bloch retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter J. Mariani appointed CFO effective Aug 14, 2024; previously CFO of Axogen (2016-2023).","Mariani receives base salary of $425,000, cash bonus up to 45%, and inducement awards of stock options & RSUs.","Kathleen P. Bloch retired as CFO and will serve as consultant at $335/hour through Dec 31, 2025.","CEO highlights Mariani's experience as company pursues U.S. FDA/Health Canada approval for DrugSorb-ATR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203959,"accession_number":"0001104659-24-089068","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents Q2 product sales up 10%, operating loss halved; DrugSorb-ATR submission on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $9.9M (+5% YoY); product sales $8.8M (+10%); gross margins improved to 75%.","Operating loss narrowed 48% to $3.4M from $6.6M; additional cost cuts expected to save $5M annually.","CFO Kathleen Bloch retired; Peter Mariani appointed as new CFO effective August 14, 2024.","On track to submit DrugSorb-ATR marketing applications to U.S. FDA and Health Canada this quarter.","Secured $20M credit facility with Avenue Capital; cash and restricted cash $14.9M as of June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":19680928.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203958,"accession_number":"0001104659-24-084908","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CytoSorbents regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 26, 2024 confirming compliance after closing bid price at $1.00+ for 10 consecutive days through July 25.","Previously, on May 22, 2024, Nasdaq notified CytoSorbents of non-compliance due to bid price below $1.00 for 30 consecutive days.","Compliance had to be achieved by November 16, 2024; the company regained compliance early from July 12 to July 25.","CEO Dr. Phillip Chan stated the company is now in full compliance, strengthening its position ahead of expected DrugSorb-ATR regulatory submissions.","CytoSorbents continues aggressive cost cutting and operational progress on clinical, regulatory, and manufacturing fronts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203957,"accession_number":"0001104659-24-077866","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CytoSorbents secures $20M credit facility with Avenue Capital; $10M available at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial tranche $15M with $10M immediately available; $5M released upon FDA acceptance of DrugSorb-ATR De Novo.","Interest rate Prime + 5% (floor 13.5%); maturity July 2027 (extendable to Jan 2028 if full tranche drawn).","Lenders receive warrants for 1,645,569 shares and conversion option on up to $2M principal at 120% of closing price.","Proceeds to fund CytoSorb global commercialization, DrugSorb-ATR FDA/Health Canada submissions, and refinance Bridge Bank debt.","Trailing 12-month CytoSorb sales $32.2M as of March 31, 2024; DrugSorb-ATR TAM in US/Canada >$0.5B if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220605,"accession_number":"0001104659-24-070039","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytoSorbents shareholders elect directors, approve executive compensation and plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees (Phillip Chan, Michael Bator, Edward Jones, Alan Sobel, Jiny Kim) elected with majority of votes cast.","Advisory vote on named executive officer compensation passed (24.3M for, 4.7M against, 0.3M abstain).","Plan Amendment to 2014 Long-term Incentive Plan approved (20.0M for, 9.0M against, 0.2M abstain).","Ratification of WithumSmith+Brown as independent auditor for FY2024 approved (37.5M for, 1.4M against).","Approximately 40.0M shares voted out of 54.3M outstanding, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220604,"accession_number":"0001104659-24-064300","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CytoSorbents receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on May 20, 2024 for non-compliance with Minimum Bid Price Requirement.","Has 180 calendar days, until November 16, 2024, to regain compliance.","To regain compliance, closing bid price must be $1.00 or more for 10 consecutive business days.","If not compliant by deadline, Nasdaq will provide delisting notice; Company may appeal.","Company intends to monitor and consider options, but no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220603,"accession_number":"0001104659-24-059457","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents Q1 product sales up 14% to $9.0M; gross margin expands to 76%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $9.0M, +14% YoY from $7.9M and +22% sequentially from Q4 2023 ($7.3M).","Product gross margins 76% (excl. $304K one-time adjustment), up from 68% in Q1 2023.","Total revenue $9.8M (+4% YoY) as grant income fell 48% to $0.8M on completion of prior grants.","Plans FDA De Novo and Health Canada submissions for DrugSorb-ATR in Q3 2024; STAR-T data presented at AATS.","Cash $10.1M (incl. $1.5M restricted) expected to fund operations into Q4 2024; seeking non-dilutive financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":9786292.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220602,"accession_number":"0001104659-24-057514","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"CytoSorbents amends bylaws: adds forum selection clause, updates advance notice provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws effective May 2, 2024; removes stockholder list inspection requirement per DGCL update.","Updated advance notice disclosure requirements for stockholder proposals and director nominations.","Deleted requirement for stockholder action to be at a duly called meeting, consistent with DGCL.","Added forum selection clause: internal affairs litigated in Delaware; securities claims in federal court."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220601,"accession_number":"0001104659-24-042809","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CytoSorbents executives take salary reduction; CEO by 35%, others by 15%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Phillip Chan reduces salary by 35% ($123,498) to $359,353 through Dec 31, 2024.","CFO Kathleen Bloch reduces salary by 15% ($46,587) to $378,413; same for other NEOs.","Board grants nonqualified stock options equal in value to each reduction at $0.95/share.","Options vest fully on Jan 31, 2025; expired 10 years from grant date.","Program aims to cut costs; salaries automatically restore to prior level after 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240234,"accession_number":"0001104659-24-034674","cik":1175151,"company_name":"Cytosorbents Corp","ticker":"CTSO","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).","Product gross margin improved to 72% from 70%; expects 75-80% in 2024.","STAR-T trial selected for Breakout Presentation at AATS (April 2024); FDA/Health Canada submission planned for H2 2024.","Ended 2023 with $15.6M cash; cost cuts include 15% RIF; cash runway into Q4 2024.","Entered India partnership with Eris Lifesciences; plan to launch PuriFi pump in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30116360.71176112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}